Thrombopoietin and Platelet Production in Chronic Immune Thrombocytopenia

Hematology/Oncology Clinics of North America

Volumn 23, Issue 6, 2009, Pages 1193-1211

  Kuter, David J ^a,b   Gernsheimer, Terry B ^c,d  

^a HARVARD MEDICAL SCHOOL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d PUGET SOUND BLOOD CENTER   (United States)

Author keywords

ITP; Platelets; Thrombocytopenia; Thrombopoietin; TPO

Indexed keywords

AKR 501; BUTYZAMIDE; CORTICOSTEROID; ELTROMBOPAG; IMMUNOGLOBULIN; LGD 4665; NIP 004; NIP 022; PEGYLATED RECOMBINANT MEGAKARYOCYTE GROWTH AND DEVELOPMENT FACTOR; PLACEBO; PREDNISONE; RECOMBINANT MEGAKARYOCYTE GROWTH AND DEVELOPMENT FACTOR; RECOMBINANT THROMBOPOIETIN; RHESUS D ANTIBODY; ROMIPLOSTIM; THROMBOPOIETIN; THROMBOPOIETIN RECEPTOR; UNCLASSIFIED DRUG;

BLEEDING; CELL DESTRUCTION; CELL SURVIVAL; CLINICAL FEATURE; CLINICAL TRIAL; DISEASE SEVERITY; DRUG APPROVAL; DRUG EFFICACY; DRUG MEGADOSE; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG TOLERABILITY; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; MEGAKARYOCYTE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN SECRETION; REGULATORY MECHANISM; REVIEW; SINGLE DRUG DOSE; SPLENECTOMY; THROMBOCYTE COUNT; THROMBOCYTOPENIA; THROMBOCYTOPOIESIS;

BIOMIMETICS; BLOOD PLATELETS; CHRONIC DISEASE; HUMANS; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; THROMBOPOIETIN;

EID: 70450043949     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hoc.2009.09.001     Document Type: Review

References (91)

1. Riverius L. On pestilential feavers. In: Culpepper N. (Ed). The practice of physick (1668), Streator, London 618
2. Werlhof P.G. Opera omnia. Hanover, Helwig, 1775, 748. In: Major R. (Ed). Classical descriptions of disease. 3rd edition (1965), CC Thomas, Springfield (IL)
3. Willan R. On cutaneous diseases (1808), J.G. Barnard, London p. 452
4. Wright J.H. The histogenesis of the blood platelets. J Morphol 21 (1910) 263
5. Wright J.H. The origin and nature of blood plates. Boston Med Surg J 154 (1906) 643
6. Wright J.H. A rapid method for the differential staining of blood films and malarial parasites. J Med Res 7 (1902) 138
7. Minot G. Studies on a case of idiopathic purpura hemorrhagica. Am J Med Sci 152 (1916) 48
8. Frank E. Die essentielle thrombopenie. Berl Klin Wochenschr 52 (1915) 454 [in German]
9. Kaznelson P. Verschwinden der hamorrhagische diathese bei einem falle von "essentieller thrombopene" (Frank) nach milzexstirpation. Splenogene thrombolytische purpura. Wien Klin Wochenschr 29 (1916) 1451 [in German]
10. Yoshida Y. Historical review. The light and shadow of Paul Kaznelson: his life and contribution to hematology. Ann Hematol 87 (2008) 877
11. Harrington W.J., Minnich V., Hollingsworth J.W., et al. Demonstration of a thrombocytopenic factor in the blood of patients with thrombocytopenic purpura. J Lab Clin Med 38 (1951) 1
12. Shulman N.R., Marder V.J., and Weinrach R.S. Comparison of immunologic and idiopathic thrombocytopenia. Trans Assoc Am Physicians 77 (1964) 65
13. Shulman N.R., Marder V.J., and Weinrach R.S. Similarities between known antiplatelet antibodies and the factor responsible for thrombocytopenia in idiopathic purpura. Physiologic, serologic and isotopic studies. Ann N Y Acad Sci 124 (1965) 499
14. Shulman N.R., Weinrach R.S., Libre E.P., et al. The role of the reticuloendothelial system in the pathogenesis of idiopathic thrombocytopenic purpura. Trans Assoc Am Physicians 78 (1965) 374
15. Harker L.A. Kinetics of thrombopoiesis. J Clin Invest 47 (1968) 458
16. Harker L.A. Regulation of thrombopoiesis. Am J Phys 218 (1970) 1376
17. Harker L.A., and Finch C.A. Thrombokinetics in man. J Clin Invest 48 (1969) 963
18. McIntosh B., and Kaushansky K. Transcriptional regulation of bone marrow thrombopoietin by platelet proteins. Exp Hematol 36 (2008) 799
19. Peck-Radosavljevic M., Wichlas M., Zacherl J., et al. Thrombopoietin induces rapid resolution of thrombocytopenia after orthotopic liver transplantation through increased platelet production. Blood 95 (2000) 795
20. Peck-Radosavljevic M., Zacherl J., Meng Y.G., et al. Is inadequate thrombopoietin production a major cause of thrombocytopenia in cirrhosis of the liver?. J Hepatol 27 (1997) 127
21. Kuter D.J., Beeler D.L., and Rosenberg R.D. The purification of megapoietin: a physiological regulator of megakaryocyte growth and platelet production. Proc Natl Acad Sci U S A 91 (1994) 11104
22. Yang C., Li J., and Kuter D.J. The physiological response of thrombopoietin (c-Mpl ligand) to thrombocytopenia in the rat. Br J Haematol 105 (1999) 478
23. Li J., Xia Y., and Kuter D.J. Interaction of thrombopoietin with the platelet c-mpl receptor in plasma: binding, internalization, stability and pharmacokinetics. Br J Haematol 106 (1999) 345
24. Scheding S., Bergmann M., Shimosaka A., et al. Human plasma thrombopoietin levels are regulated by binding to platelet thrombopoietin receptors in vivo. Transfusion 42 (2002) 321
25. Emmons R.V., Reid D.M., Cohen R.L., et al. Human thrombopoietin levels are high when thrombocytopenia is due to megakaryocyte deficiency and low when due to increased platelet destruction. Blood 87 (1996) 4068
26. Harker L.A., Marzec U.M., Hunt P., et al. Dose-response effects of pegylated human megakaryocyte growth and development factor on platelet production and function in nonhuman primates. Blood 88 (1996) 511
27. Kaushansky K. Lineage-specific hematopoietic growth factors. N Engl J Med 354 (2006) 2034
28. de Sauvage F.J., Carver-Moore K., Luoh S.M., et al. Physiological regulation of early and late stages of megakaryocytopoiesis by thrombopoietin. J Exp Med 183 (1996) 651
29. de Sauvage F.J., Villeval J.L., and Shivdasani R.A. Regulation of megakaryocytopoiesis and platelet production: lessons from animal models. J Lab Clin Med 131 (1998) 496
30. Alexander W.S., Roberts A.W., Nicola N.A., et al. Deficiencies in progenitor cells of multiple hematopoietic lineages and defective megakaryocytopoiesis in mice lacking the thrombopoietic receptor c-Mpl. Blood 87 (1996) 2162
31. Carver-Moore K., Broxmeyer H.E., Luoh S.M., et al. Low levels of erythroid and myeloid progenitors in thrombopoietin- and c-mpl-deficient mice. Blood 88 (1996) 803
32. Ballmaier M., Germeshausen M., Schulze H., et al. c-mpl mutations are the cause of congenital amegakaryocytic thrombocytopenia. Blood 97 (2001) 139
33. Ihara K., Ishii E., Eguchi M., et al. Identification of mutations in the c-mpl gene in congenital amegakaryocytic thrombocytopenia. Proc Natl Acad Sci U S A 96 (1999) 3132
34. van den Oudenrijn S., Bruin M., Folman C.C., et al. Mutations in the thrombopoietin receptor, Mpl, in children with congenital amegakaryocytic thrombocytopenia. Br J Haematol 110 (2000) 441
35. McMillan R., Wang L., Tomer A., et al. Suppression of in vitro megakaryocyte production by antiplatelet autoantibodies from adult patients with chronic ITP. Blood 103 (2004) 1364
36. Nichol J.L. Thrombopoietin levels after chemotherapy and in naturally occurring human diseases. Curr Opin Hematol 5 (1998) 203
37. Kuter D.J. The physiology of platelet production. Stem Cells 14 (1996) 88
38. Dameshek W., and Miller E. The megakaryocytes in idiopathic thrombocytopenic purpura, a form of hypersplenism. Blood 1 (1946) 27
39. Aster R.H., and Jandl J.H. Platelet sequestration in man. I. Methods. J Clin Invest 43 (1964) 843
40. Najean Y., Ardaillou N., Dresch C., et al. The platelet destruction site in thrombocytopenic purpuras. Br J Haematol 13 (1967) 409
41. Branehog I., Kutti J., and Weinfeld A. Platelet survival and platelet production in idiopathic thrombocytopenic purpura (ITP). Br J Haematol 27 (1974) 127
42. Thakur M.L., Welch M.J., Joist J.H., et al. Indium-LLL labeled platelets: studies on preparation and evaluation of in vitro and in vivo functions. Thromb Res 9 (1976) 345
43. Ballem P.J., Segal G.M., Stratton J.R., et al. Mechanisms of thrombocytopenia in chronic autoimmune thrombocytopenic purpura. Evidence of both impaired platelet production and increased platelet clearance. J Clin Invest 80 (1987) 33
44. 51Cr-labeled platelets differ. Blood 67 (1986) 86
45. Hanson S.R., and Slichter S.J. Platelet kinetics in patients with bone marrow hypoplasia: evidence for a fixed platelet requirement. Blood 66 (1985) 1105
46. Gernsheimer T., Stratton J., Ballem P.J., et al. Mechanisms of response to treatment in autoimmune thrombocytopenic purpura. N Engl J Med 320 (1989) 974
47. Stratton J.R., Ballem P.J., Gernsheimer T., et al. Platelet destruction in autoimmune thrombocytopenic purpura: kinetics and clearance of indium-111-labeled autologous platelets. J Nucl Med 30 (1989) 629
48. Louwes H., Vellenga E., Houwerzijl E.J., et al. Effects of prednisone and splenectomy in patients with idiopathic thrombocytopenic purpura: only splenectomy induces a complete remission. Ann Hematol 80 (2001) 728
49. Li S., Wang L., Zhao C., et al. CD8+ T cells suppress autologous megakaryocyte apoptosis in idiopathic thrombocytopenic purpura. Br J Haematol 139 (2007) 605
50. Kuter D.J. Thrombopoietin and thrombopoietin mimetics in the treatment of thrombocytopenia. Annu Rev Med 60 (2009) 193
51. Kuter D.J. New drugs for familiar therapeutic targets: thrombopoietin receptor agonists and immune thrombocytopenic purpura. Eur J Haematol Suppl 69 (2008) 9
52. Kuter D.J. New thrombopoietic growth factors. Blood 109 (2007) 4607
53. Kuter D.J. Thrombopoietin: biology, clinical applications, role in the donor setting. J Clin Apheresis 11 (1996) 149
54. Kuter D.J. Thrombopoietins and thrombopoiesis: a clinical perspective. Vox Sang 74 (1998) 75
55. Frey B.M., Rafii S., Teterson M., et al. Adenovector-mediated expression of human thrombopoietin cDNA in immune- compromised mice: insights into the pathophysiology of osteomyelofibrosis. J Immunol 160 (1998) 691
56. Villeval J.L., Cohen-Solal K., Tulliez M., et al. High thrombopoietin production by hematopoietic cells induces a fatal myeloproliferative syndrome in mice. Blood 90 (1997) 4369
57. Yan X.Q., Lacey D., Hill D., et al. A model of myelofibrosis and osteosclerosis in mice induced by overexpressing thrombopoietin (mpl ligand): reversal of disease by bone marrow transplantation. Blood 88 (1996) 402
58. Basser R.L., Rasko J.E., Clarke K., et al. Thrombopoietic effects of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) in patients with advanced cancer. Lancet 348 (1996) 1279
59. Fanucchi M., Glaspy J., Crawford J., et al. Effects of polyethylene glycol-conjugated recombinant human megakaryocyte growth and development factor on platelet counts after chemotherapy for lung cancer. N Engl J Med 336 (1997) 404
60. Harker L.A., Hunt P., Marzec U.M., et al. Regulation of platelet production and function by megakaryocyte growth and development factor in nonhuman primates. Blood 87 (1833) 1996
61. Kuter D.J., and Begley C.G. Recombinant human thrombopoietin: basic biology and evaluation of clinical studies. Blood 100 (2002) 3457
62. Goodnough L.T., Kuter D.J., McCullough J., et al. Prophylactic platelet transfusions from healthy apheresis platelet donors undergoing treatment with thrombopoietin. Blood 98 (2001) 1346
63. Kuter D.J., Goodnough L.T., Romo J., et al. Thrombopoietin therapy increases platelet yields in healthy platelet donors. Blood 98 (2001) 1339
64. Vadhan-Raj S., Kavanagh J.J., Freedman R.S., et al. Safety and efficacy of transfusions of autologous cryopreserved platelets derived from recombinant human thrombopoietin to support chemotherapy-associated severe thrombocytopenia: a randomised cross-over study. Lancet 359 (2002) 2145
65. Li J., Yang C., Xia Y., et al. Thrombocytopenia caused by the development of antibodies to thrombopoietin. Blood 98 (2001) 3241
66. Cwirla S.E., Balasubramanian P., Duffin D.J., et al. Peptide agonist of the thrombopoietin receptor as potent as the natural cytokine. Science 276 (1997) 1696
67. Bussel J.B., Kuter D.J., George J.N., et al. AMG 531, a thrombopoiesis-stimulating protein, for chronic ITP. N Engl J Med 355 (2006) 1672
68. Wang B., Nichol J.L., and Sullivan J.T. Pharmacodynamics and pharmacokinetics of AMG 531, a novel thrombopoietin receptor ligand. Clin Pharmacol Ther 76 (2004) 628
69. Broudy V.C., and Lin N.L. AMG531 stimulates megakaryopoiesis in vitro by binding to Mpl. Cytokines 25 (2004) 52
70. Kuter D.J., Mufti G., Bain B., et al. Evaluation of bone marrow reticulin formation in romiplostim-treated adult patients with chronic ITP. Blood 112 (2008) 1171a
71. ODAC meeting briefing document. Available at:http://www.fda.gov/ohrms/dockets/ac/08/briefing/2008-4345b1-02-AMGEN. pdf. Accessed November 5, 2008.
72. Kuter D.J., Bussel J.B., Lyons R.M., et al. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. Lancet 371 (2008) 395
73. Duffy K.J., Darcy M.G., Delorme E., et al. Hydrazinonaphthalene and azonaphthalene thrombopoietin mimics are nonpeptidyl promoters of megakaryocytopoiesis. J Med Chem 44 (2001) 3730
74. Duffy K.J., Price A.T., Delorme E., et al. Identification of a pharmacophore for thrombopoietic activity of small, non-peptidyl molecules. 2. Rational design of naphtho[1,2-d]imidazole thrombopoietin mimics. J Med Chem 45 (2002) 3576
75. Jenkins J.M., Williams D., Deng Y., et al. Phase 1 clinical study of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist. Blood 109 (2007) 4739
76. Desjardins R.E., Tempel D.L., Lucek R., et al. Single and multiple oral doses of AKR-501 (TM477) increase the platelet count in healthy volunteers. Blood 108 (2006) 145a
77. Dziewanowska Z.E., Matsumoto R.M., Zhang J.K., et al. Single and multiple oral doses of LGD-4665, a small molecule thrombopoietin receptor agonist, increase platelet counts in healthy male subjects. Blood 110 (2007) 1298
78. Nakamura T., Miyakawa Y., Miyamura A., et al. A novel nonpeptidyl human c-Mpl activator stimulates human megakaryopoiesis and thrombopoiesis. Blood 107 (2006) 4300
79. Nogami W., Yoshida H., Koizumi K., et al. The effect of a novel, small non-peptidyl molecule butyzamide on human thrombopoietin receptor and megakaryopoiesis. Haematologica 93 (2008) 1495
80. Yamane N., Takahashi K., Tanaka Y., et al. Discovery of novel non-peptide thrombopoietin mimetic compounds that induce megakaryocytopoiesis. Biosci Rep 28 (2008) 275
81. Yamane N., Tanaka Y., Ohyabu N., et al. Characterization of novel non-peptide thrombopoietin mimetics, their species specificity and the activation mechanism of the thrombopoietin receptor. Eur J Pharmacol 586 (2008) 44
82. Jenkins J., Nicholl R., Williams D., et al. An oral, non-peptide, small molecule thrombopoietin receptor agonist increases platelet counts in healthy subjects. Blood 104 (2004) 797a
83. Bussel J.B., Cheng G., Saleh M.N., et al. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N Engl J Med 357 (2007) 2237
84. Erickson-Miller C., Delorme E., Iskander M., et al. Species specificity and receptor domain interaction of a small molecule TPO receptor agonist. Blood 104 (2004) 795a
85. Fukushima-Shintani M., Suzuki K., Iwatsuki Y., et al. AKR-501 (YM477) in combination with thrombopoietin enhances human megakaryocytopoiesis. Exp Hematol 36 (2008) 1337
86. Nomura S., Dan K., Hotta T., et al. Effects of pegylated recombinant human megakaryocyte growth and development factor in patients with idiopathic thrombocytopenic purpura. Blood 100 (2002) 728
87. Rice L., Nichol J.L., McMillan R., et al. Cyclic immune thrombocytopenia responsive to thrombopoietic growth factor therapy. Am J Hematol 68 (2001) 210
88. Cole J.L., Marzec U.M., Gunthel C.J., et al. Ineffective platelet production in thrombocytopenic human immunodeficiency virus-infected patients. Blood 91 (1998) 3239
89. Harker L.A., Carter R.A., Marzec U.M., et al. Correction of thrombocytopenia and ineffective platelet production in patients infected with human immunodeficiency virus (HIV) by PEG-rHuMGDF therapy. Blood 92 (1998) 707a
90. Harker L.A., Marzec U.M., Novembre F., et al. Treatment of thrombocytopenia in chimpanzees infected with human immunodeficiency virus by pegylated recombinant human megakaryocyte growth and development factor. Blood 91 (1998) 4427
91. Houwerzijl E.J., Blom N.R., van der Want J.J., et al. Ultrastructural study shows morphologic features of apoptosis and para-apoptosis in megakaryocytes from patients with idiopathic thrombocytopenic purpura. Blood 103 (2004) 500